Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors : a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non–small cell lung cancer
Ding, P. N., Lord, S. J., Gebski, V. J., Links, M., Bray, V. J., Gralla, R. J., … Lee, C. (2017). Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors : a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non–small cell lung cancer. Journal Of Thoracic Oncology, 12(4), 633-643. https://doi.org/doi:10.1016/j.jtho.2016.11.2236
![](/sites/all/themes/uws-themec/images/Visible17.png)
![](/sites/all/themes/uws-themec/images/Down12.png)